Clinical Trial Update: A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BMS-790052 in combination with BMS-650032 in Japanese patients with hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-650032
• BMS-790052 (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED